Evidence map›Paper›PMID 34878902›Full record

ArticleJournal of virology2022

Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection.

Yudi Zhang, Qihong Yan, Kun Luo, Ping He, Ruitian Hou, Xinwei Zhao, Qian Wang, Haisu Yi, Huan Liang, Yijun Deng and 11 more

Abstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Explore antibody repertoire in the era of AI.Acta biochimica et biophysica Sinica · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yudi Zhang *Bioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Qihong Yan *Bioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Kun Luo *Bioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Ping HeBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Ruitian HouBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Xinwei ZhaoBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Qian WangState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Haisu YiState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Huan LiangState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yijun DengState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Fengyu HuGuangzhou Institute of Infectious Disease, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Feng LiGuangzhou Institute of Infectious Disease, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Xinglong LiuBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Ying FengBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Pingchao LiBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Linbing QuBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Zhaoming ChenBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.
Qiang Pan-HammarströmDepartment of Biosciences and Nutrition, Karolinska Institutet, Solna. Sweden.
Liqiang FengBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.ORCID 0000-0001-6811-2074
Xuefeng NiuState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ling ChenBioland Laboratory, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Healthgrid.428926.3, Chinese Academy of Sciences, Guangzhou, China.ORCID 0000-0003-1485-1626

Funding

China Evergrande Group 2020GIRHHMS22Chinese Academy of Sciences Pilot Strategic Science and Technology Projects XDB29050701National Natural Science Foundation of China (NSFC) 32170941National Natural Science Foundation of China (NSFC) 82041014National Natural Science Foundation of China (NSFC) 82061138006Zhongnanshan Medical Foundation of Guangdong Province ZNSA-2020001
6 · The paper itself

Abstract

A comprehensive study of the B cell response against SARS-CoV-2 could be significant for understanding the immune response and developing therapeutical antibodies and vaccines. To define the dynamics and characteristics of the antibody repertoire following SARS-CoV-2 infection, we analyzed the mRNA transcripts of immunoglobulin heavy chain (IgH) repertoires of 24 peripheral blood samples collected between 3 and 111 days after symptom onset from 10 COVID-19 patients. Massive clonal expansion of naive B cells with limited somatic hypermutation (SHM) was observed in the second week after symptom onset. The proportion of low-SHM IgG clones strongly correlated with spike-specific IgG antibody titers, highlighting the significant activation of naive B cells in response to a novel virus infection. The antibody isotype switching landscape showed a transient IgA surge in the first week after symptom onset, followed by a sustained IgG elevation that lasted for at least 3 months. SARS-CoV-2 infection elicited poly-germ line reactive antibody responses. Interestingly, 17 different IGHV germ line genes recombined with IGHJ6 showed significant clonal expansion. By comparing the IgH repertoires that we sequenced with the 774 reported SARS-CoV-2-reactive monoclonal antibodies (MAbs), 13 shared spike-specific IgH clusters were found. These shared spike-specific IgH clusters are derived from the same lineage of several recently published neutralizing MAbs, including CC12.1, CC12.3, C102, REGN10977, and 4A8. Furthermore, identical spike-specific IgH sequences were found in different COVID-19 patients, suggesting a highly convergent antibody response to SARS-CoV-2. Our analysis based on sequencing antibody repertoires from different individuals revealed key signatures of the systemic B cell response induced by SARS-CoV-2 infection.

Indexed as

Antibodies, NeutralizingAntibodies, ViralB-LymphocytesCOVID-19HumansImmunoglobulin GReceptors, Antigen, B-CellSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralImmunoglobulin GReceptors, Antigen, B-Cellantibody repertoireB cell receptorisotype switchingSARS-CoV-2shared clonotypesomatic hypermutation

Identifiers

PMID34878902
PMCPMC8865482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.